• In June 2026, United Therapeutics’ subsidiary Lung Bioengineering received U.S. FDA premarket approval for LungFX, a centralized ex vivo lung perfusion device that allows transplant centers to reassess marginal deceased-donor lungs outside the body before transplantation.
• This approval marks the first EVLP system cleared specifically for use in dedicated centralized facilities, potentially broadening access to advanced lung assessment for hospitals that lack in-house EVLP infrastructure while also introducing new clinical risk–benefit considerations for transplant teams.
• We’ll now examine how LungFX’s centralized EVLP approval could reshape United Therapeutics’ organ-transplant platform within its broader investment narrative.

Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.

United Therapeutics Investment Narrative Recap

To own United Therapeutics, you need to believe its core pulmonary drugs can keep funding a high-risk, long-horizon push into organ manufacturing and xenotransplantation. The LungFX approval looks directionally supportive of that organ platform but does not change the near term focus on Tyvaso IPF readouts or the key risk around heavy dependence on PAH and pulmonary therapies in the face of intensifying competition.

Among recent developments, the FDA clearance to begin the EXPRESS xenotransplant study with the UHeart program sits closest in spirit to LungFX. Together, LungFX and UHeart highlight United Therapeutics’ attempt to build an integrated transplant ecosystem, where devices, engineered organs and cardiopulmonary drugs intersect, even as pipeline setbacks or slower adoption could challenge the long term payoff from this ambitious innovation wave.

However, investors should also be aware that the clinical risk profile seen in LungFX’s pivotal data raises questions about...

United Therapeutics' narrative projects $4.5 billion revenue and $1.8 billion earnings by 2029.

Uncover how United Therapeutics' forecasts yield a $665.23 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Some analysts were far more optimistic before LungFX, projecting revenue of about US$5,000,000,000 and earnings near US$2,200,000,000 by 2029, while you weigh how organ manufacturing risk and xenotransplantation timelines might evolve as this new device data filters into the story.

Explore 3 other fair value estimates on United Therapeutics - why the stock might be worth just $665.23!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your United Therapeutics research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free United Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate United Therapeutics' overall financial health at a glance.

Interested In Other Possibilities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 45 companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 15 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.